** Shares of artificial intelligence (AI) biologics firm
Absci ABSI.O rise ~10% to $1.91 premarket
** Company said on Sunday it has signed a deal worth up to
$247 mln with AstraZeneca AZN.L to design a cancer-fighting
antibody
** The deal aims for a zero-shot generative AI model
designed to create new and improved antibody therapeutics - ABSI
** ABSI did not say what kind of cancer it plans to target
** The company applies generative AI to design optimal drug
candidates based on target affinity, safety, manufacturability
and other traits
** Up to last close, ABSI shares down 17.1% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))